What constitutes target validation?

Drug Discovery Today: TARGETS

Volumn 2, Issue 4, 2003, Pages 125-127

  Peet, Norton P ^a,b  

^a Aurigene Discovery Technologies   (United States)

^b Aurigene Discovery Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APTAMER; DOUBLE STRANDED RNA; DRUG CARRIER; LOCKED NUCLEIC ACID; METHYLPHOSPHONIC ACID; MONOCLONAL ANTIBODY; PEPTIDE NUCLEIC ACID; RIBOZYME; RNA DIRECTED RNA POLYMERASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; ZINC FINGER PROTEIN;

COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TARGETING; EDITORIAL; GENE OVEREXPRESSION; HUMAN; KNOCKOUT GENE; NONHUMAN; PROTEIN ENGINEERING; RNA INTERFERENCE; SIDE EFFECT; VALIDATION PROCESS;

EID: 1042287092     PISSN: 17418372     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1477-3627(03)02317-1     Document Type: Editorial

References (24)

1. Pimstone, S. (2002) Old-fashioned genetics remains genomics' best friend. Business briefing. Pharmatechnology 1, 88-90
2. Henning, S.W. and Beste, G. (2002) Loss-of-function strategies in drug target validation. Curr. Drug Discov. May, 17-21
3. Thompson, J.D. (2002) Applications of antisense and siRNAs during preclinical development. Drug Discov. Today 7, 912-917
4. Bennett, C.F. and Cowsert, L.M. (1999) Application of antisense oligunucleotides for gene functionalization and target validation. Curr. Opin. Mol. Ther. 1, 359-371
5. Bennett, C.F. (1998) Antisense oligunucleotides: is the glass half full or half empty? Biochem. Pharmacol. 55, 9-19
6. Baker, B.F. et al. (2001) Discovery and analysis of antisense oligunucleotide activity in cell culture. Methods 23, 191-198
7. Agrawal, S. (1999) Importance of nucleotide sequence and chemical modification of antisense oligunucleotides. Biochim. Biophys. Acta 1489, 53-68
8. Adah, S.A. et al. (2001) Chemistry and biochemistry of 2,5-oligoadenylate-based antisense strategy. Curr. Med. Chem. 8, 1189-1212
9. Nielsen, P.E. et al. (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254, 1497-1500
10. Iversen, P.I. (2001) Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene in activation. Curr. Opin. Mol. Ther. 3, 235-238
11. Orum, H. and Wengel, J. (2001) Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development. Curr. Opin. Mol. Ther. 3, 239-243
12. Hogrefe, R.I. (1999) An antisense oligonucleotide primer. Antisense Nucleic Acid Drug Dev. 9, 351-357
13. Schlingensiepen, R. and Schlingensiepen, K. W. (1997) Antisense oligodeoxynucleotides - highly specific tools for basic research and pharmacotherapy. In Antisense - From Technology to Therapy (Schlingeusiepen, R. and Brysch, W., eds), pp 3-28, Blackwell
14. Fire, A. et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811
15. Sharp, P.A. (2001) RNA interference - 2001. Genes Dev. 15, 485-490
16. Elbashir, S.M. et al. (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15, 188-200
17. Garber, K. (2003) Prescription RNA. Technol. Rev. 1, 42-48
18. Zanders, E.D. et al. (2002) Probes for chemical genomics by design. Drug Discov. Today 7, 711-718
19. MacBeath, G. (2001) Chemical genomics: what will it take and who gets to play? Genome Biol. 2
20. Burgstaller, P. et al. (2002) Aptamers as tools for target prioritization and lead identification. Drug Discov. Today 7, 1221-1228
21. Bell, S.D. et al. (1998) RNA molecules that bind to and inhibit the active site of a tyrosine phosphatase. J. Biol. Chem. 273, 14309-14314
22. Kusser, W. (2000) Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution. J. Biotechnol. 74, 27-38
23. Leva, S. et al. (2002) GnRH binding RNA and DNA spiegelmers. A novel approach toward GnRH antagonism. Chem. Biol. 9, 351-359
24. Wlotzka, B. et al. (2002) In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc. Natl. Acad. Sci. U. S. A. 99, 8898-8902